Details for Patent: 12,005,062

Which drugs does patent 12,005,062 protect, and when does it expire?

Patent 12,005,062 protects LIQREV and is included in one NDA.

This patent has nine patent family members in nine countries.

Recent additions to Drugs Protected by US Patent 12,005,062

These patents are from the daily update and have not yet been integrated into the regular database

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Req.	Patent Expiration	Usecode	Patented / Exclusive Use
Cmp Dev Llc	LIQREV	sildenafil citrate	SUSPENSION	214952	Apr 28, 2023	DISCN	Yes		Y				U-3582	LIQREV IS INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS TO IMPROVE EXERCISE ABILITY AND DELAY CLINICAL WORSENING

Drugs Protected by US Patent 12,005,062

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cmp Dev Llc	LIQREV	sildenafil citrate	SUSPENSION;ORAL	214952-001	Apr 28, 2023		DISCN	Yes	No			Y			LIQREV IS INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS TO IMPROVE EXERCISE ABILITY AND DELAY CLINICAL WORSENING

International Family Members for US Patent 12,005,062

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018397436
Brazil	112020012986
Canada	3086881